Form 8-K - Current report:
SEC Accession No. 0001479290-24-000022
Filing Date
2024-02-13
Accepted
2024-02-13 16:28:38
Documents
15
Period of Report
2024-02-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20240207.htm   iXBRL 8-K 31107
2 EX-10.1 rvncespexhibit101.htm EX-10.1 197326
  Complete submission text file 0001479290-24-000022.txt   388905

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20240207.xsd EX-101.SCH 1939
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20240207_lab.xml EX-101.LAB 24139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20240207_pre.xml EX-101.PRE 12544
17 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20240207_htm.xml XML 2822
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 24626478
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)